IRLAB A — IRLAB Therapeutics AB Income Statement
0.000.00%
Last trade - 00:00- SEK366.71m
- SEK360.21m
- SEK94.63m
Annual income statement for IRLAB Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 208 | 61.1 | 5.68 | 94.6 |
| Cost of Revenue | |||||
| Gross Profit | -65.6 | 126 | -64.8 | -123 | -41.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 91.5 | 155 | 174 | 186 | 170 |
| Operating Profit | -91.5 | 52.6 | -113 | -181 | -75.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -91.7 | 51.8 | -113 | -178 | -83.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -91.7 | 51.8 | -113 | -178 | -83.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -91.7 | 51.8 | -113 | -178 | -83.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -91.7 | 51.8 | -113 | -178 | -83.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.92 | 1 | -2.19 | -3.43 | -1.6 |
| Dividends per Share |